Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Drug Des Devel Ther · 2017 · PMC5503498 · PMID 28740365

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

74 PROs showed a trend toward improved symptom burden and QoL was maintained during treatment.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.